Glimepiride attenuates Aβ production via suppressing BACE1 activity in cortical neurons

Neuroscience Letters

Volumn 557, Issue PB, 2013, Pages 90-94

  Liu, Feiyang ^a   Wang, Yijin ^a   Yan, Ming ^a   Zhang, Luyong ^a   Pang, Tao ^a   Liao, Hong ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Amyloid; Alzheimer's disease; BACE1; Glimepiride; PPAR agonist

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; BETA SECRETASE 1; GLIMEPIRIDE; MESSENGER RNA;

ANIMAL CELL; ARTICLE; BRAIN CELL; CELL LEVEL; CONTROLLED STUDY; DRUG ANTAGONISM; ENZYME ACTIVITY; ENZYME INHIBITION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; RAT; RECEPTOR DOWN REGULATION;

3-(4,5-DIMETHYLTHIAZOL-2-YL)-2,5-DIPHENYLTETRAZOLIUM BROMIDE; AD; ALZHEIMER'S DISEASE; AΒ; BACE1; DIABETES MELLITUS; DIMETHYL SULFOXIDE; DM; DMSO; ELISA; ENZYME-LINKED IMMUNOSORBENT ASSAY; GAPDH; GLIMEPIRIDE; GLP-1; GLUCAGON-LIKE PEPTIDE-1; GLYCERALDEHYDE-3-PHOSPHATEDEHYDROGENASE; MTT; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR Γ; PPARΓ; PPARΓ AGONIST; REAL-TIME POLYMERASE CHAIN REACTION; RT-PCR; THIAZOLIDINEDIONES; TZDS; Β-AMYLOID; Β-AMYLOID PEPTIDE; Β-SITE APP-CLEAVING ENZYME 1;

AMYLOID BETA-PEPTIDES; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; ASPARTIC ACID ENDOPEPTIDASES; BLOTTING, WESTERN; CELLS, CULTURED; CEREBRAL CORTEX; ENZYME-LINKED IMMUNOSORBENT ASSAY; HYPOGLYCEMIC AGENTS; NEURONS; RATS; REAL-TIME POLYMERASE CHAIN REACTION; SULFONYLUREA COMPOUNDS;

EID: 84888057816     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2013.10.052     Document Type: Article

References (32)

1. Bowman G.L., Kaye J.A., Moore M., Waichunas D., Carlson N.E., Quinn J.F. Blood-brain barrier impairment in Alzheimer disease: stability and functional significance. Neurology 2007, 68:1809-1814.
2. Camacho I.E., Serneels L., Spittaels K., Merchiers P., Dominguez D., De Strooper B. Peroxisome proliferator-activated receptor gamma induces a clearance mechanism for the amyloid-beta peptide. J. Neurosci. 2004, 24:10908-10917.
3. Chen Y., Zhou K., Wang R., Liu Y., Kwak Y.D., Ma T., Thompson R.C., Zhao Y., Smith L., Gasparini L., Luo Z., Xu H., Liao F.F. Antidiabetic drug metformin (GlucophageR) increases biogenesis of Alzheimer's amyloid peptides via up-regulating BACE1 transcription. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:3907-3912.
4. Cole S.L., Vassar R. The Alzheimer's disease beta-secretase enzyme, BACE1. Mol. Neurodegener. 2007, 2:22.
5. De Felice F.G., Vieira M.N., Bomfim T.R., Decker H., Velasco P.T., Lambert M.P., Viola K.L., Zhao W.Q., Ferreira S.T., Klein W.L. Protection of synapses against Alzheimer's-linked toxins: insulin signaling prevents the pathogenic binding of Abeta oligomers. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:1971-1976.
6. Farret A., Lugo-Garcia L., Galtier F., Gross R., Petit P. Pharmacological interventions that directly stimulate or modulate insulin secretion from pancreatic beta-cell: implications for the treatment of type 2 diabetes. Fundam. Clin. Pharmacol. 2005, 19:647-656.
7. Fukuen S., Iwaki M., Yasui A., Makishima M., Matsuda M., Shimomura I. Sulfonylurea agents exhibit peroxisome proliferator-activated receptor gamma agonistic activity. J. Biol. Chem. 2005, 280:23653-23659.
8. Gengler S., McClean P.L., McCurtin R., Gault V.A., Holscher C. Val(8)GLP-1 rescues synaptic plasticity and reduces dense core plaques in APP/PS1 mice. Neurobiol. Aging 2012, 33:265-276.
9. Gouras G.K., Xu H., Jovanovic J.N., Buxbaum J.D., Wang R., Greengard P., Relkin N.R., Gandy S. Generation and regulation of beta-amyloid peptide variants by neurons. J. Neurochem. 1998, 71:1920-1925.
10. Hanson L.R., Frey W.H. Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease. BMC Neurosci. 2008, 9:S5.
11. Inukai K., Watanabe M., Nakashima Y., Takata N., Isoyama A., Sawa T., Kurihara S., Awata T., Katayama S. Glimepiride enhances intrinsic peroxisome proliferator-activated receptor-gamma activity in 3T3-L1 adipocytes. Biochem. Biophys. Res. Commun. 2005, 328:484-490.
12. Irie F., Fitzpatrick A.L., Lopez O.L., Kuller L.H., Peila R., Newman A.B., Launer L.J. Enhanced risk for Alzheimer disease in persons with type 2 diabetes and APOE epsilon4: the cardiovascular health study cognition study. Arch. Neurol. 2008, 65:89-93.
13. Jiang Q., Heneka M., Landreth G.E. The role of peroxisome proliferator-activated receptor-gamma (PPARgamma) in Alzheimer's disease: therapeutic implications. CNS Drugs 2008, 22:1-14.
14. Kawamori R., Morishima T., Kubota M., Matsuhisa M., Ikeda M., Kamada T. Influence of oral sulfonylurea agents on hepatic glucose uptake. Diabetes Res. Clin. Pract. 1995, 28:S109-S113.
15. Langtry H.D., Balfour J.A. Glimepiride. A review of its use in the management of type 2 diabetes mellitus. Drugs 1998, 55:563-584.
16. Lee K.W., Ku Y.H., Kim M., Ahn B.Y., Chung S.S., Park K.S. Effects of sulfonylureas on peroxisome proliferator-activated receptor r activity and on glucose uptake by thiazolidinediones. Diabetes Metab. J. 2011, 35:340-347.
17. Li Y., Duffy K.B., Ottinger M.A., Ray B., Bailey J.A., Holloway H.W., Tweedie D., Perry T., Mattson M.P., Kapogiannis D., Sambamurti K., Lahiri D.K., Greig N.H. Glp-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease. J. Alzheimers Dis. 2010, 19:1205-1219.
18. Moloney A.M., Griffin R.J., Timmons S., O'Connor R., Ravid R., O'Neill C. Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signalling. Neurobiol. Aging (Milano) 2010, 31:224-243.
19. Müller G., Dearey E.A., Punter J. The sulphonylurea drug, glimepiride, stimulates release of glycosylphosphatidylinositol-anchored plasma-membrane proteins from 3T3 adipocytes. J. Biochem. 1993, 289:509-521.
20. Olson R.E., Marcin L.R. Secretase inhibitors and modulators for the treatment of Alzheimer's disease. Annual Reports in Medicinal Chemistry 2007, 27-47. Academic Press, (Chapter 3).
21. Ott A., Stolk R.P., van Harskamp F., Pols H.A., Hofman A., Breteler M.M. Diabetes mellitus and the risk of dementia: the Rotterdam study. Neurology 1999, 53:1937-1942.
22. Qin W., Haroutunian V., Katsel P., Cardozo C.P., Ho L., Buxbaum J.D., Pasinetti G.M. PGC-1alpha expression decreases in the Alzheimer disease brain as a function of dementia. Arch. Neurol. 2009, 66:352-361.
23. Reger M.A., Watson G.S., Green P.S., Wilkinson C.W., Baker L.D., Cholerton B., Fishel M.A., Plymate S.R., Breitner J.C., DeGroodt W., Mehta P., Craft S. Intranasal insulin improves cognition and modulates beta-amyloid in early AD. Neurology 2008, 70:440-448.
24. Sastre M., Dewachter I., Rossner S., Bogdanovic N., Rosen E., Borghgraef P., Evert B.O., Dumitrescu-Ozimek L., Thal D.R., Landreth G., Walter J., Klockgether T., van Leuven F., Heneka M.T. Nonsteroidal anti-inflammatory drugs repress beta-secretase gene promoter activity by the activation of PPARgamma. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:443-448.
25. Sato T., Hanyu H., Hirao K., Kanetaka H., Sakurai H., Iwamoto T. Efficacy of PPAR-γ agonist pioglitazone in mild Alzheimer disease. Neurobiol. Aging 2011, 32:1626-1633.
26. Scarsi M., Podvinec M., Roth A., Hug H., Kersten S., Albrecht H., Schwede T., Meyer U.A., Rucker C. Sulfonylureas and glinides exhibit peroxisome proliferator-activated receptor gamma activity: a combined virtual screening and biological assay approach. Mol. Pharmacol. 2007, 71:398-406.
27. Starr J.M., Wardlaw J., Ferguson K., MacLullich A., Deary I.J., Marshall I. Increased blood-brain barrier permeability in type II diabetes demonstrated by gadolinium magnetic resonance imaging. J. Neurol. Neurosurg. Psychiatry 2003, 74:70-76.
28. Steen E., Terry B.M., Rivera E.J., Cannon J.L., Neely T.R., Tavares R., Xu X.J., Wands J.R., de la Monte S.M. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease-is this type 3 diabetes?. J. Alzheimers Dis. 2005, 7:63-80.
29. Testa M.A., Simonson D.C. Health economic benefits and quality of life during improved glycemic control in patients with type 2 diabetes mellitus: a randomized, controlled, double-blind trial. JAMA 1998, 280:1490-1496.
30. Tomlinson D.R., Gardiner N.J. Glucose neurotoxicity. Nat. Rev. Neurosci. 2008, 9:36-45.
31. Wang L.F., Zhang R., Xie X. Development of a high-throughput assay for screening of gamma-secretase inhibitor with endogenous human, mouse or Drosophila gamma-secretase. Molecules 2009, 14:3589-3599.
32. Xu W., Caracciolo B., Wang H.X., Winblad B., Backman L., Qiu C., Fratiglioni L. Accelerated progression from mild cognitive impairment to dementia in people with diabetes. Diabetes 2010, 59:2928-2935.